52157-82-1

Usage

Uses

Used in Research Applications:
5-METHOXY-3-PIPERIDIN-4-YL-1H-INDOLE is used as a research chemical for studying the effects of psychedelics on the brain. It aids scientists in understanding the mechanisms of action and potential therapeutic applications of hallucinogenic substances.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 5-METHOXY-3-PIPERIDIN-4-YL-1H-INDOLE is used as a lead compound in the development of new medications. Its psychoactive properties are of interest for potential therapeutic applications in treating mental health disorders such as depression and anxiety.
Used in Recreational Settings:
Although not recommended due to its psychoactive effects and potential health risks, 5-METHOXY-3-PIPERIDIN-4-YL-1H-INDOLE is used recreationally by some individuals for its hallucinogenic properties, which can lead to altered states of consciousness and perception.

InChI:InChI=1/C14H18N2O/c1-17-11-2-3-14-12(8-11)13(9-16-14)10-4-6-15-7-5-10/h2-3,8-10,15-16H,4-7H2,1H3

Upstream product

• 41661-47-6 piperidin-4-one 
• 1006-94-6 5-methoxylindole 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 1314-15-4 platinum(IV) oxide 
• 30030-80-9 3-(1-acetyl-1,4-dihydro-4-pyridyl)-5-methoxy-1H-indole 
• 52157-81-0 5-methoxy-3-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]-1H-indole 
• 951174-11-1 tert-butyl-4-(5-methoxy-1H-indol-3-yl)piperidine-1-carboxylate 
• 66611-26-5 5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole 
• 111608-71-0 3-(1-acetyl-4-piperidyl)-5-methoxyindole 
• 41979-39-9 4-piperidone hydrochloride 
• 40064-34-4 4-piperidone monohydrochloride monohydrate 

Downstream Products

• 299173-58-3 (E)-3-(3,4-dichlorophenyl)-N-{5-[4-(5-methoxy-1H-indol-3-yl)-piperidin-1-yl]pentyl}acrylamide 
• 116966-92-8 8-[4-{4-(5-methoxy-1H-indol-3-yl)-1-piperidinyl}-butyl]-8-azaspiro[4,5]decane-7,9-dione 
• 1149339-77-4 2-{4-[4-(5-methoxy-1H-indol-3-yl)piperidin-1-yl]-butyl}-4-phenylpyrido[1,2-c]pyrimidine-1,3-dione 
• 1149339-76-3 4-(2-fluorophenyl)-2-{4-[4-(5-methoxy-1H-indol-3-yl)piperidin-1-yl]butyl}pyrido[1,2-c]pyrimidine-1,3-dione 
• 1149339-75-2 4-(4-fluorophenyl)-2-{4-[4-(5-methoxy-1H-indol-3-yl)piperidin-1-yl]butyl}pyrido[1,2-c]pyrimidine-1,3-dione 
• 1149339-72-9 2-{4-[4-(5-methoxy-1H-indol-3-yl)piperidin-1-yl]-butyl}-4-(4-methoxyphenyl)pyrido[1,2-c]pyrimidine-1,3-dione 
• 1149339-73-0 2-{4-[4-(5-methoxy-1H-indol-3-yl)piperidin-1-yl]-butyl}-4-p-tolyl-pyrido[1,2-c]pyrimidine-1,3-dione 
• 1149339-74-1 4-(4-chlorophenyl)-2-{4-[4-(5-methoxy-1H-indol-3-yl)piperidin-1-yl]butyl}pyrido[1,2-c]pyrimidine-1,3-dione 
• 177939-72-9 5-methoxy-3-<1-<2-<1-phenyl-1H-pyrazol-4-yl>ethyl>-4-piperidinyl>-1H-indole 
• 1198318-38-5 2-{4-[4-(5-methoxy-1H-indol-3-yl)-piperidin-1-yl]-butyl}-4-o-tolyl-5,6,7,8-tetrahydro-pyrido[1,2-c]pyrimidine-1,3-dione 
• 1198318-30-7 2-{4-[4-(5-methoxy-1H-indol-3-yl)-piperidin-1-yl]-butyl}-4-p-tolyl-5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine-1,3-dione 
• 1198318-33-0 4-(2-fluorophenyl)-2-{4-[4-(5-methoxy-1H-indol-3-yl)-piperidin-1-yl]-butyl}-5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine-1,3-dione 

Relevant academic research and scientific papers

Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect

A series of novel 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives were synthesised and evaluated for their 5-HT1A/D2/5-HT2A/5-HT6/5-HT7 receptor affinity and serotonin reuptake inhibition. Most of the evaluated compounds displayed high affinities for 5-HT1A receptors (e.g., 4c Ki = 2.3 nM, 4l Ki = 3.2 nM). The antidepressant activity of the selected compounds was screened in vivo using the forced swim test (FST). The results indicate that compound MW005 (agonist of the pre- and postsynaptic 5-HT1A receptor) exhibited promising affinities for the 5-HT1A/SERT/D2/5-HT6/5-HT7 receptors and showed an antidepressant-like activity in the FST model.

Substituted heterocyclic compounds and application of same to medicines

The invention relates to substituted heterocyclic compounds and application of the same to medicines and specifically provides the novel substituted heterocyclic compounds or stereoisomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, and preparation methods thereof. The invention also relates to pharmaceutical compositions containing the compounds and application of the compounds or pharmaceutical compositions to treatment of diseases related to 5-HT6 receptors, especially Alzheimer's disease.

Substituted heterocyclic compounds and its application on the medicament (by machine translation)

The invention relates to substituted heterocyclic compounds and its application on the medicament, in particular to a novel class of substituted heterocyclic compounds or its isomer, tautomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug, and their method of preparation. The invention also relates to the compounds of the invention pharmaceutical composition, and said compound or pharmaceutical compositions for the treatment5-HT6receptor-related diseases, in particular Alzheimer's disease in the use thereof. (by machine translation)

Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents. Part 1

A series of 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives was synthesized and their biological activity was evaluated. The chemical structures of the newly prepared compounds were confirmed by 1H NMR, 13C NMR and ESI-HRMS spectra data. All tested compounds proved to be potent 5-HT1A receptor and serotonin transporter protein (SERT) ligands. Among them, compounds 15, 18, 19 and 30 showed significant affinity for 5-HT1A and SERT. Computer docking simulations carried out for compounds 15, 31 and 32 to models of 5-HT1A receptor and SERT confirm the results of biological tests. Due to high affinity for the 5-HT1A receptor and moderate affinity for SERT, compounds 31, 32, 35, and 37 were evaluated for their affinity for D2L, 5-HT6, 5-HT 7 and 5-HT2A receptors. In vivo tests, in turn, resulted in determining the functional activity of compounds 15, 18, 19 and 30 to the 5-HT1A receptor. The results of these tests indicate that all of the ligands possess properties characteristic of 5-HT1A receptor agonists.

Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity, Part 1

A series of new derivatives of 4-aryl-pyrido[1,2-c]pyrimidine containing the 3-(4-piperidyl)-1H-indole residue or its 5-methoxy derivative were synthesized. They were characterized (i) in vitro by binding to 5-HT1A receptors and 5-HT transporter proteins in rat brain cortex membranes and (ii) in vivo in the mouse by induced hypothermia and forced swimming models for antagonist/agonist activity against the 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors, respectively. Structure activity relationship evaluation indicated that the presence of the 3-(4-piperidyl)-1H-indole residue and ortho- or para-substituents with -F or -CH3 groups in the aryl ring as well as an unsubstituted aryl in the 4-aryl-pyrido[1,2-c]pyrimidine moiety promoted low Ki values for both receptors. In contrast, the presence of a 5-methoxy-3-(4-piperidyl)-1H-indole residue as well as -Cl or -OCH3 substituents at the para position markedly reduced the receptor affinity.

Polystyrene sulfonyl chloride: A highly orthogonal linker resin for the synthesis of nitrogen-containing heterocycles

One linker, broad application: A simple sulfonamide linker for primary and secondary amines was used for the construction of small libraries of privileged indole and quinolone structures on a solid phase. After the synthesis, the products can be liberated ion a traceless manner under electron transfer conditions or according to a "safety catch" principle.

Pyrazole-based cathepsin S inhibitors with improved cellular potency

High potency pyrazole-based noncovalent inhibitors of human cathepsin S (CatS) were developed by modification of the benzo-fused 5-membered ring heterocycles found in earlier series of CatS inhibitors. Although substitutions on this heterocyclic framework

ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines of formula (I) and their use in therapy.

ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA

This invention relates to novel compounds which up-regulate LDL receptor (LDL-r) expression. and to processes for their preparation, pharmaceutical compositions containing them and their medical use. More particularly, this invention relates to novel aromatic piperidines of formula (I) and their use in therapy. wherein Ar1 is substituted, by at least one R1 group selected from: -O(CRaRb)nC(O)NRXRy, -O(CH2)nCN, -O(CH2)nO(CH2)mOR2, -O(CH2)nCO2R2, -OS02NRxRy, -OSO2(CH2)pCH3, -(CRaRb)nC(O)NRXRy, -(CH2)nCN, -(CH2)nO(CH2)mOR2, -(CH2)nCO2R2, -(CH2)nC(O)R2, - SO2NRxRy, -SO2(CH2)pCH3, -CH=CHC(O)NRxRy, -CH=CHCN, -CH=CHCO2R2, -CO2R2, - C(O)R2, -C(O)NRxRy and C2-5alkenyl.

4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS

The invention relates to 4-substituted 1-aminocyclohexane derivatives of general formula (I), to a method for the production thereof, to medicaments containing said compounds and to the utilization of 4-substituted 1-aminocyclohexane derivatives for the production of medicaments.